From the Advisory Board

June 2023, Vol 4, No 2 — June 30, 2023

Combined hepatocellular cholangiocarcinoma (cHCC-CCA) is a unique malignancy comprised of both hepatocellular carcinoma (HCC) from hepatocytes and cholangiocarcinoma (CCA) from bile duct epithelial cells within the same tumor. Initially thought to be a rare entity, the incidence is increasing (up to 14%), yet recognition remains low.

Surgical Management and Neoadjuvant Therapy for Cholangiocarcinoma

By Flavio G. Rocha, MD, FACS, FSSO

September 2022, Vol 3, No 3 — September 28, 2022

Surgery remains the only potentially curative modality for cholangiocarcinoma (CCA) in any site of origin.

Immunotherapy in Cholangiocarcinoma: Coming of Age

By Richard Kim, MD; Amit Mahipal, MBBS, MPH

From the Advisory Board

June/July 2022, Vol 3, No 2 — August 18, 2022

Recent advances in genomic profiling and critical understanding of pathophysiology have led to the development of multiple targeted therapies in addition to chemotherapeutic agents.

From the Advisory Board

Subscribe Today!

I'd like to receive:

Stay In The Know